Clinical utility of leflunomide for BK polyomavirus associated nephropathy in kidney transplant recipients: A multicenter retrospective study.
Nicolas KellerSimon DuquennoyAnne ConradSamira Fafi-KremerEmmanuel MorelonNicolas BouvierBruno MoulinBruno Hurault De LignySophie CaillardPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2019)
We cannot conclude about the exact place of leflunomide in the therapeutic strategy of BKPyVAN. It may be a part of the therapy to promote BK polyomavirus clearance in cases of BKPyVAN who fail to improve after immunosuppression lowering alone. Unfortunately, a significant decline in renal function and high rejection rates remain major clinical challenges.